China Cord Blood Corporation Announces Completion of $65 Million Convertible Debt Financing with KKR
China Cord Blood Corporation (NYSE: CO)today announced that it has successfully closed a US$65 million convertible debt financing with funds affiliated with KKR China Growth Fund L.P., a China-focused investment fund managed by Kohlberg Kravis Roberts & Co. L.P.. The transaction was first announced on April 12, 2012.
The convertible debt carries a 7% interest per annum and inclusive of the interest, a total internal rate of return of 12% per annum. With a maturity of five years, the convertible debt holder can convert the convertible debt into ordinary shares of the Company at a conversion price of $2.838, subject to customary anti-dilutive adjustments. On a fully converted basis, the total ordinary shares issuable represents approximately 23.8% of the enlarged share capital of the Company.
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.